ProBio and AbTis Partner to Develop Next-Generation Cancer ADC
ProBio has entered into an exclusive global licensing agreement with South Korean biotechnology company AbTis to develop a new antibody-drug conjugate (ADC) for cancer treatment. The…
Read More...
Read More...
